Somese

Quick links to important sections

Somese

Method of action: Hypnotic, Psycholeptics

Treatment option: Insomnia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Somese

What is Somese? (Triazolam)

Property Description
Active ingredient Triazolam
Form Oral Tablet
Pharmacological class Benzodiazepine, Hypnotic
Common use Short-term management of sleep-onset insomnia
Origin Synthetic Compound

What Type of Medicine is Somese (Triazolam)?

Somese is the trade name for the active ingredient Triazolam, a synthetic compound that is classified as a potent benzodiazepine derivative. It is a single-ingredient drug defined pharmacologically as a hypnotic agent and a Central Nervous System (CNS) depressant. Triazolam is recognized as an imidazole-fused benzodiazepine. This classification signifies the drug's ultra-short-acting profile, and it is consistently supplied as an oral tablet and remains a strictly prescription-only medication.

What is the General Purpose of This Short-Acting Hypnotic?

The primary, generalized purpose of Somese is the management of sleep-onset insomnia in adults. It is intended for short-term treatment, specifically to facilitate the process of falling asleep quickly. Triazolam is intended for use for relatively brief periods, generally not exceeding seven to ten days. This use scenario highlights its function as a temporary intervention, leveraging its rapid metabolism to address the immediate need for sleep induction while minimizing lingering sedation.

How Does Somese Work in Simple Terms?

Somese works by enhancing the natural inhibitory effects of the neurotransmitter gamma-aminobutyric acid (GABA).

Regulatory References

  1. National Library of Medicine
  2. [PubChem, CID 5556]
  3. [MedlinePlus]

What side effects are possible with Somese?

Possible Side Effects and Safety Information

The safety profile of Somese (Triazolam) is defined by its classification as a potent CNS depressant, with adverse reactions organized by frequency and system-organ class in official regulatory documents.

Common and Expected Adverse Reactions

The most frequently documented side effects in clinical trials are predominantly central nervous system (CNS)-related, consistent with the drug's hypnotic function. These effects, classified as Most Common in regulatory documents, include drowsiness, headache, dizziness, light-headedness, nervousness, and coordination disorder (ataxia). Less common reactions documented include euphoria, tachycardia, and visual disturbances.

Serious Adverse Reactions and Safety Concerns

The official labeling notes the risk of rare but serious reactions. These include the occurrence of complex sleep-related behaviors while not fully awake (e.g., "sleep-driving") with amnesia for the event. Rarely, severe hypersensitivity reactions such as angioedema of the larynx have been documented. The medication carries a recognized risk of physical dependence, abuse, and misuse, which can lead to severe, potentially life-threatening withdrawal symptoms upon abrupt discontinuation.

Population and Exposure Safety Notes

Specific regulatory considerations apply to certain populations. Older adults are known to be more sensitive to dose-related CNS adverse reactions like confusion and dizziness. For all patients, the safety profile notes that certain effects, such as rebound insomnia (worsening of sleep after stopping treatment) and increased daytime anxiety, may be associated with the drug’s short duration of action or discontinuation. Additionally, the label explicitly restricts use with specific strong CYP3A inhibitors and notes the increased risks of profound sedation when combined with alcohol or other CNS depressants.

Overdose and Emergency Response

Somese Overdose and When to Seek Help

The information in this section outlines the official documented overdose profile for Somese (Triazolam) as stated in government regulatory sources.

Category Official Regulatory Statements
Documented overdose presentations Overdose is characterized by an exaggeration of central nervous system (CNS) depression, presenting with somnolence, confusion, slurred speech, lethargy, impaired coordination (ataxia), and diminished reflexes.
Physiological systems affected CNS and the potential for Respiratory Depression and Cardiovascular Depression in severe cases.
Dose-related or exposure-related factors Severe outcomes, including coma, are more likely to occur when the product is ingested in amounts substantially exceeding the prescribed dose or in combination with other CNS depressants, including alcohol or opioids.
Population-specific overdose notes The elderly and patients with hepatic or renal impairment may experience heightened sensitivity, which could lead to more severe manifestations of overdose.
Emergency-response statements Management is primarily symptomatic and supportive. Required measures include monitoring of respiration, pulse, and blood pressure. Procedures such as gastric lavage or administration of activated charcoal may be employed to prevent further absorption.
When immediate medical help is required Seek immediate medical attention for any suspected overdose. Contact emergency services if severe symptoms such as slow breathing or unresponsiveness occur.

Official overdose statements:

  • The specific benzodiazepine receptor antagonist Flumazenil is documented as a possible intervention, though its use must be weighed against the risk of precipitating seizures.
  • Patients with persistent CNS depression or compromised vital signs require management in a hospital-monitored setting.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Somese overdose profile by the degree of CNS depression, establishing a range of outcomes from mild lethargy to severe outcomes like respiratory depression or coma. This regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose, particularly when the amount ingested is excessive or mixed with other CNS depressants, ensuring the availability of necessary supportive measures.

Therapeutic Uses of Somese

What Somese Treats: Main Uses and Benefits

The use of Somese (Triazolam) is centered on providing targeted, short-term symptomatic support primarily within the domain of sleep initiation and specific procedural contexts. It is applied when symptoms that interfere with daily functioning create a noticeable, temporary interference with a patient's stability.

The medication is generally used for the short-term treatment of insomnia in adults.

Addressing Symptomatic Domains

This medication is commonly used across conditions presenting with acute episodes of sleep-onset insomnia. The medication is applied in addressing the symptom of prolonged sleep latency, and is considered relevant in conditions involving episodic sleep disturbances, such as those experienced due to jet lag or brief stress, and anticipatory distress before medical procedures. The core benefit provided is the facilitation of sleep induction, which supports general well-being by helping to ease the overall symptom burden.

“This medication is considered relevant in clinical settings that involve acute or disruptive symptom patterns, offering symptomatic relief that helps patients cope with difficult episodes.”

Quick Fact & Primary Uses

Quick Fact: Relief for Initial Sleeplessness

Somese is commonly used to help manage symptoms of increased neurological or muscular activity that prevent rest, and is considered relevant when short-term symptomatic assistance is needed. This application provides supportive relief during phases when symptoms become more noticeable due to circadian rhythm misalignment, contributing to easing the overall symptom burden during periods of heightened symptoms.

Regulatory References

  1. Official FDA Label Information via NIH DailyMed

Eligibility and Restrictions for Use

Eligibility Scope for Somese (Triazolam)

Official regulatory documents define the population eligible for Somese use as adults requiring short-term treatment. Use is strictly limited by several major contraindications and population restrictions.

Absolute Contraindications

Somese is contraindicated and must not be used by the following groups:

  • Patients with a known hypersensitivity or allergy to triazolam or to other benzodiazepines.
  • Pregnant women (classified as Category X by the FDA), due to the potential risk of fetal harm.
  • Patients concurrently receiving potent inhibitors of Cytochrome P450 3A (CYP 3A), such as ketoconazole, itraconazole, and nefazodone, as specified in the prescribing information.

Age and Condition Restrictions

Classification Population or Condition Regulatory Status
Pediatric Use Children and adolescents below 18 years of age Safety and efficacy have not been established; use is not recommended.
Geriatric Use Older adults (Geriatric patients) Eligible, but use is restricted to a lower maximum daily dose due to increased sensitivity.
Lactation Status Nursing mothers (Breastfeeding) Use is not recommended.
Organ Function Severe Hepatic Insufficiency Classified as contraindicated in some regional regulatory documents.
Comorbidity Chronic Respiratory Insufficiency, Sleep Apnoea, Myasthenia Gravis Use requires caution or may be contraindicated depending on severity and region.

Eligibility is further constrained, requiring caution for patients with a history of drug or alcohol abuse or pre-existing depressive disorders.

What should I know about interactions with other medicines?

The official interaction profile for Somese (Triazolam) is characterized by critical constraints related to its metabolism and pharmacodynamic effects.

The most stringent restriction is the contraindication of co-administration with medicinal products that are strong inhibitors of the CYP3A enzyme. This pharmacokinetic interaction prevents the clearance of Somese, leading to a substantial increase in its plasma concentration and a risk of serious adverse outcomes. Prohibited combinations include specific azole antifungals (e.g., ketoconazole, itraconazole) and certain HIV Protease Inhibitors (e.g., ritonavir, cobicistat).

Significant warnings apply to substances causing additive Central Nervous System (CNS) depression, a pharmacodynamic interaction. Concomitant use with opioids carries a risk of profound sedation, respiratory depression, and coma. Ingestion of alcohol (ethanol) must also be avoided due to additive CNS depressant effects. Furthermore, the consumption of grapefruit juice must be avoided as it is documented to increase Triazolam's bioavailability.

Regulatory documents note that other moderate CYP3A inhibitors (e.g., cimetidine, erythromycin) may increase drug levels and reduce clearance, requiring caution. The documentation also includes notes regarding population-specific vulnerability, stating that the outcomes of CNS depressant interactions may be more pronounced in elderly and debilitated patients.

Mechanism of Action

Somese is a small-molecule drug that exerts its effect by specifically inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme essential in the mevalonate pathway. This specific interaction prevents the normal prenylation of small GTPase signaling proteins.

The inhibition of FPPS reduces the intracellular concentration of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). These two compounds are required for the post-translational modification of regulatory proteins within osteoclasts, leading to an alteration of their cytoskeletal structure and a reduction in their resorptive activity.

The net reduction in osteoclast-mediated bone resorption shifts the balance toward osteoblast-mediated bone formation, resulting in a systemic decrease in the rate of bone turnover.

Dosage and Administration Information

How to Use Somese (Triazolam): Administration Guidelines

Somese (Triazolam) is administered via the oral route as a tablet. Usage is defined by the specific conditions under which the medicine is taken to ensure intended effect.

Administration Pattern and Frequency

The medication is designed for once-daily use and must be taken immediately before bedtime. This timing is essential for aligning the drug’s ultra-short action profile with the requirement for sleep induction. It is a fundamental instruction that the tablet should not be taken with or right after a heavy meal.

Crucially, the tablet should only be consumed when the user is able to commit to a full 7 to 8 hours of sleep before any activity is required. Taking the medicine with less time available may lead to residual impairment upon waking.

Standard Dosing and Duration

For adults, the recommended starting dose is 0.25 mg once daily. The dose may be initiated at 0.125 mg for certain patients, and the maximum dosage should not exceed 0.5 mg once daily.

Treatment is indicated for the short-term management of insomnia, and should generally not exceed seven to ten days. Use extending beyond two to three weeks involves a complete patient re-evaluation.

Population-Specific Use

Specific dosage limits are set for certain populations. For older adults (geriatric patients), therapy is initiated at the low dose of 0.125 mg once daily, and the maximum allowed dose should not exceed 0.25 mg per day. A lower starting dose of 0.125 mg is also recommended for debilitated patients or those with impaired liver function.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section provides an overview of the clinical research that evaluated the safety and efficacy of the combination drug. The studies focused on patients with chronic inflammatory conditions.


Phase I and Phase II Studies

Early-stage research concentrated on defining the pharmacological parameters of the combined agents.

  • Phase I: Studies investigated the absorption, distribution, metabolism, and excretion (ADME) of the drug in healthy volunteers. No unexpected pharmacokinetic interactions between the two components were reported.
  • Phase II: Research has examined the action of the drug by combining these two agents, focusing on dose-ranging. The studies focused solely on the effects of the combined agent.

Findings: The studies defined a dosage that was carried forward into later-stage trials.


Phase III Randomized Controlled Trials (RCTs)

The primary focus of Phase III trials was to compare the combination drug against each individual agent and a placebo.

Efficacy Endpoints

Key efficacy measures included changes in standardized pain scales (e.g., VAS, NPRS) and objective biological markers of inflammation (e.g., CRP, ESR).

  • A key finding indicated that the combined use was assessed for its association with pain scores and inflammatory markers.
  • Studies investigated whether this combination therapy differed in effect onset when compared to individual agents.
  • Phase III trials explored whether the combination showed differing results. Efficacy outcomes were assessed for variation across the various patient subgroups studied.

Safety and Tolerability

Safety analysis across the Phase III studies involved monitoring for adverse events (AEs), conducting laboratory assessments, and measuring vital signs.

  • Safety analysis recorded specific adverse events, including gastrointestinal upset and temporary fatigue.
  • Determining the clinical suitability of the drug is outside the scope of this research overview. Safety data remains under continuous review.

Frequently Asked Questions (FAQ)

Common questions about Somese (FAQ)


Q: What makes Somese different from other medicines that treat the same thing?

Official pharmacological documents classify Somese (triazolam) as a hypnotic agent characterized by its ultra-short half-life. This means the medicine is processed and leaves the body relatively quickly, which is a key distinguishing feature of its action profile compared to other medicines in the same class.


Q: Is it necessary to take Somese at the exact same time every day?

Official guidance emphasizes that the medication should be taken immediately before bedtime as part of its once-daily use. This timing aligns with the instruction that the medicine should only be consumed when a full 7 to 8 hours of sleep is possible before any required activity.


Q: How long does it usually take before I might notice the effects of Somese?

Based on regulatory information, the active ingredient's peak plasma concentration—when the drug's amount in the body is highest—is typically reached within two hours after the tablet is taken orally. This pharmacological profile is consistent with its intended function to help with quickly initiating sleep.


Q: If Somese is stopped suddenly, are there any expected changes?

Discontinuing Somese after taking it continuously may be associated with symptoms such as rebound insomnia, where sleep problems temporarily return or worsen. To reduce the potential for withdrawal reactions, regulatory guidance advises that any change to the treatment plan, including discontinuation, may require a gradual dose reduction.


Q: Can people with kidney problems use Somese?

Official dosing guidelines indicate that the use of Somese in patients with renal impairment (kidney problems) requires caution. Regulatory documents indicate that use in this population may require adjustment to the administration protocol as determined by a healthcare provider.


Q: Is Somese ever prescribed for pregnant or breastfeeding women?

Regulatory documents state that Somese is contraindicated for use during pregnancy because of the potential risk of fetal harm. Furthermore, its use is not recommended in nursing mothers (breastfeeding women).


Q: Can I drive or operate machinery while taking Somese?

Due to its function as a Central Nervous System (CNS) depressant, official labeling advises patients to be cautioned against engaging in hazardous occupations that require complete mental alertness. These activities include operating machinery or driving a motor vehicle.


Q: What should I do if I miss a scheduled dose of Somese?

If a dose is occasionally missed, patient information resources indicate that the missed dose should not be taken later in the night. The medicine should be taken as prescribed on the next scheduled night to avoid potential residual impairment upon waking.


Q: Is Somese a controlled substance?

Yes, Somese is classified as a Schedule IV controlled substance by the Drug Enforcement Administration (DEA). This classification is a recognition of its potential for abuse, misuse, and dependence, and it governs how the drug is prescribed and dispensed.


Q: Does Somese contain any ingredients people might be allergic to?

The drug is officially contraindicated for anyone with a known hypersensitivity or allergy to its active ingredient, triazolam, or to any of the other inactive ingredients (excipients) used to form the tablet. The full product labeling contains a complete list of these ingredients.


Q: If my symptoms feel worse initially, is that a normal reaction to Somese?

Official warnings note that new or worsening abnormal thoughts and changes in behavior have been reported with benzodiazepine use. If initial worsening of symptoms or new behavioral changes are experienced, official labeling notes that such changes warrant consultation with a healthcare professional.


Q: Is there a generic version of Somese available?

Yes, Somese is the brand name for the generic active ingredient, triazolam. This generic form of the medicine is generally available, as described in regulatory product information.


Q: Is Somese known to cause weight changes?

Clinical reviews of reported side effects indicate that weight loss has been noted as a rare adverse reaction associated with the medication. However, this is not listed as a common or expected side effect in the official documents.


Q: Can Somese be split, crushed, or chewed?

The product is manufactured as an oral tablet. Official guidance for administration generally states that patients should swallow the tablet whole. Altering the tablet by crushing, splitting, or chewing is generally not advised unless otherwise specifically indicated by a healthcare provider.


Q: Are there any known long-term side effects associated with Somese use?

Somese is formally indicated for short-term use only, typically for 7 to 10 days. Using the medicine for longer periods increases the risks of side effects, including the development of physical dependence and potential for abuse and misuse, as outlined in official warnings.


Q: Do the side effects of Somese go away after taking it for a while?

Regulatory documents list the most common side effects as CNS-related, such as dizziness and drowsiness. While the official information does not give a specific timeframe for resolution, it does note that risks like daytime anxiety can increase after as few as 10 days of continuous use.


Q: Is Somese known to affect mood or mental state?

Yes, official labeling reports that the drug may be associated with various mental and behavioral changes. These include reactions like euphoria, agitation, and even the reporting of new or worsening depression.


Q: Does taking Somese with food change how it works?

Administration guidelines specifically advise that the tablet should not be taken with or immediately after a heavy meal. This is because food can alter how the body absorbs and processes the medication, potentially affecting its intended action.


Q: How quickly does Somese start to leave the body?

Official pharmacological data characterizes the active ingredient as having a short mean plasma half-life. This half-life is reported to be in the range of 1.5 to 5.5 hours, which reflects how quickly the body reduces the drug's concentration.

How should Somese be stored and disposed of?

The storage and disposal of Somese (Triazolam) must strictly follow official regulatory requirements to ensure stability and safety.

Required Storage Conditions

Somese oral tablets must be kept at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The product must be protected from moisture, excessive heat, and freezing. It is required to keep the medication in its original container and ensure the container is tightly closed. Due to its classification, it must be stored out of the reach and sight of children.

Official Disposal Instructions

Unused or expired Somese should be disposed of through an authorized drug take-back program. If a program is unavailable, follow the official guidelines for non-flushable controlled substances by mixing the medicine with an undesirable substance before discarding it in a sealed container in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Somese found in:

A-Z Index: